This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) | MicrobiomeTrials
← Back to trials NCT07463183
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-03-24Est. Completion: 2027-10-28
Enrollment target: 100 participantsLocations Clinnova Research ( Site 1042), Anaheim, California, United States Southern California Research Center ( Site 1044), Coronado, California, United States Peak Gastroenterology Associates ( Site 1052), Colorado Springs, Colorado, United States South Denver Gastroenterology, PC ( Site 1068), Englewood, Colorado, United States Nature Coast Clinical Research ( Site 1045), Inverness, Florida, United States Research Associates of South Florida - Miami - Southwest 8th Street ( Site 1072), Miami, Florida, United States AdventHealth Orlando ( Site 1074), Orlando, Florida, United States Gastroenterology Associates of Central Georgia ( Site 1060), Macon, Georgia, United States University of Kansas Medical Center ( Site 1077), Kansas City, Kansas, United States Tulane University School of Medicine-Gastroenterology and Hepatology ( Site 1073), New Orleans, Louisiana, United States BVL Research - Kansas ( Site 1054), Liberty, Missouri, United States Prairie Institute of Liver and Luminal Advanced Research ( Site 1008), Lethbridge, Alberta, Canada Toronto Western Hospital ( Site 1006), Toronto, Ontario, Canada Other microbiome trials you might be interested in Inflammatory Bowel Diseases (IBD) Crohn Disease Colitis, Ulcerative
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refr…
Multiple Locations Est. completion Oct 31, 2032
Inflammatory Bowel Disease
This study evaluates oral Lactobacillus reuteri as an adjunct therapy for 2 months. Endoscopic assessments will be perfo…
Suqian, China Completed Mar 30, 2026
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 1001), Montreal, Quebec, Canada
Servicios de Salud IPS Suramericana S.A.S. - IPS Sura Industriales Medellín ( Site 1163), Medellín, Antioquia, Colombia
Clinica de la Costa S.A.S. ( Site 1161), Barranquilla, Atlántico, Colombia
Fundacion Santa Fe de Bogota ( Site 1165), Bogota, Cundinamarca, Colombia
Fundación Valle del Lili ( Site 1162), Cali, Valle del Cauca Department, Colombia
Centre Hospitalier Dr Schaffner ( Site 1288), Lens, Pas-de-Calais, France
Clinique Jules Verne ( Site 1284), Nantes, Pays de la Loire Region, France
Universitaetsklinikum Ulm. ( Site 1324), Ulm, Baden-Wurttemberg, Germany
Universitätsklinikum Brandenburg an der Havel ( Site 1323), Brandenburg, Germany
Evangelismos General Hospital of Athens ( Site 1362), Athens, Attica, Greece
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 1361), Athens, Attica, Greece
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1404), Bologna, Emilia-Romagna, Italy
Radboudumc ( Site 1650), Nijmegen, Gelderland, Netherlands
Amsterdam UMC, locatie VUmc ( Site 1651), Amsterdam, North Holland, Netherlands
PROMED P. LACH R. GLOWACKI SP. J. ( Site 1447), Krakow, Lesser Poland Voivodeship, Poland
Melita Medical Sp Zoo ( Site 1442), Wroclaw, Lower Silesian Voivodeship, Poland
EB Group Sp. Z o.o. Centrum Zdrowia MDM ( Site 1449), Warsaw, Masovian Voivodeship, Poland
Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś ( Site 1448), Warsaw, Masovian Voivodeship, Poland
Twoja Przychodnia - Szczeciskie Centrum Medyczne ( Site 1450), Szczecin, West Pomeranian Voivodeship, Poland
Wonju Severance Christian Hospital ( Site 1602), Wŏnju, Kang-won-do, South Korea
Korea University Ansan Hospital ( Site 1603), Ansan-si, Kyonggi-do, South Korea
Kangbuk Samsung Hospital ( Site 1601), Seoul, South Korea
Addenbrooke's Hospital ( Site 1525), Cambridge, Cambridgeshire, United Kingdom
Fairfield General Hospital ( Site 1524), Bury, Lancashire, United Kingdom
Guys and St Thomas NHS Foundation Trust ( Site 1523), London, London, City of, United Kingdom
Huddersfield Royal Infirmary ( Site 1522), Huddersfield, York, United Kingdom Recruiting
Recurrent C. Difficile (rCDI) Ulcerative Colitis (UC) Metabolic Syndrome (MetS)
The gut microbiota plays a key role in immunity and metabolism and contributes to diseases such as recurrent C. difficil…
Rome, Italy Est. completion Jan 19, 2029